Why Is TG Therapeutics (TGTX) Stock Down -11.15% Today?
Key Takeaways
- TG Therapeutics shares plunged 11.15% during Monday's trading session, falling from a prior close of $52.03 to $46.23, following the release of second-quarter 2026 earnings.
- The primary catalyst was a severe earnings-per-share miss: the company reported EPS of $0.05, dramatically below the consensus analyst estimate of approximately $0.31.
- Revenue beat expectations: total global revenue reached $240.3 million, up 70.3% year-over-year and above Wall Street forecasts of roughly $231 million.
- R&D spending tripled to $95.3 million from $31.8 million a year ago, driven by manufacturing investments for subcutaneous BRIUMVI and an expanding clinical pipeline.
- Full-year guidance was raised: the company lifted its 2026 total global revenue target to approximately $950 million, with BRIUMVI U.S. net product revenue now expected at $890–$905 million.
- Traders are watching upcoming pipeline catalysts including Phase 3 subcutaneous BRIUMVI data expected by early 2027 and Phase 1 azer-cel data in progressive MS later this year.
Opening Summary
TGTX, the commercial-stage biopharmaceutical company behind the multiple sclerosis drug BRIUMVI (ublituximab-xiiy), saw its stock tumble 11.15% on Monday. Shares dropped to $46.23 from Friday's closing price of $52.03, making it the steepest single-day decline for the company since early January 2026. The sell-off was triggered by TG Therapeutics' second-quarter 2026 earnings report, which revealed a dramatic EPS shortfall despite strong top-line growth and an upward revision to full-year revenue guidance.
Q2 Earnings Miss Overshadows Revenue Beat
TG Therapeutics reported second-quarter 2026 earnings of just $0.05 per share, missing the consensus analyst estimate of roughly $0.31 by a wide margin and falling well below the $0.17 per share recorded in the same quarter a year earlier. The bottom-line compression was particularly jarring to investors given that the company's revenue performance was robust. Total global revenue came in at $240.3 million, a 70.3% surge year-over-year that exceeded Wall Street expectations of approximately $231 million.
BRIUMVI, the company's anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis, continued its strong commercial trajectory. U.S. net product revenue for the drug reached $227.7 million, up 64% from the prior-year period and surpassing management's guided range of $220 million. Ex-U.S. sales to licensing partner Neuraxpharm contributed an additional $8.1 million.
The disconnect between top-line strength and bottom-line weakness stems entirely from a sharp escalation in operating expenses. Research and development spending more than tripled to $95.3 million from $31.8 million a year ago, with approximately $54.6 million of that tied directly to subcutaneous BRIUMVI manufacturing and secondary-manufacturer start-up costs. Selling, general, and administrative expenses also climbed to $82.1 million from $55.6 million, reflecting increased marketing spend and personnel costs supporting BRIUMVI's commercialization.
Raised Guidance and Pipeline Ambition
In a move that might normally support a stock, TG Therapeutics raised its full-year 2026 total global revenue target to approximately $950 million, up from its prior outlook of around $925 million. The company also lifted its U.S. BRIUMVI net product revenue guidance to $890–$905 million. CEO Michael Weiss emphasized that BRIUMVI is "on track to exit 2026 at an approximately $1 billion annualized U.S. revenue run rate."
However, the company also flagged that full-year operating expenses — including R&D and SG&A — are now expected to reach approximately $350–$400 million excluding non-cash compensation, plus an additional $100 million in subcutaneous manufacturing and secondary-supplier start-up costs. The substantial spending ramp is tied to an ambitious pipeline expansion that includes a subcutaneous formulation of BRIUMVI in Phase 3 trials, a Phase 3 ENHANCE study supporting a simplified single-infusion initiation regimen, and new clinical programs in myasthenia gravis and treatment-resistant schizophrenia. While these investments could meaningfully expand BRIUMVI's addressable market over the long term, they are punishing near-term profitability — and the market reacted accordingly.
Market Context and Trading Activity
Monday's sell-off reflected more than just an earnings disappointment. TGTX had rallied approximately 74.6% year-to-date coming into the session, significantly outperforming the broader biotech sector. With shares trading near the upper end of their 52-week range and a 50-day moving average of roughly $50.48 well below Friday's close, the stock was vulnerable to profit-taking on any perceived misstep. Today's decline pushed the stock decisively below its 50-day moving average, a technical level closely watched by traders.
Volume was elevated relative to recent sessions, signaling strong conviction behind the move. The broader market offered little shelter: while the biotech sector has generally outperformed this year, investor sentiment soured on high-multiple growth names that failed to deliver on the bottom line. The negative reaction echoed similar moves in peer biotech stocks reporting mixed second-quarter results, underscoring a market environment increasingly focused on profitability over pure revenue momentum.
What Comes Next for TGTX
Looking ahead, TGTX faces a critical period of execution. The company expects to present full Phase 3 ENHANCE trial results later this year, which could support regulatory submission for a simplified BRIUMVI initiation schedule by mid-2027. Top-line data from the pivotal Phase 3 trial of subcutaneous BRIUMVI is anticipated around year-end 2026 or early 2027 — a potentially transformative catalyst that would allow the company to compete in the self-administered segment of the anti-CD20 market, which management estimates represents 35–40% of the total opportunity.
Preliminary Phase 1 data for azer-cel, the company's allogeneic CD19 CAR T-cell therapy in progressive multiple sclerosis, is also expected in the second half of 2026. With $612.3 million in cash and investments as of June 30 and a growing revenue base, TG Therapeutics has the financial runway to fund its pipeline — but investors will closely scrutinize whether the elevated spending translates into tangible clinical and regulatory progress. Risks include potential delays in clinical timelines, payer and rebate pressures on BRIUMVI pricing, and intensifying competition in the MS space from established players like Roche's Ocrevus and Novartis' Kesimpta.
Trending AI Robots
For traders seeking data-driven insights beyond traditional fundamental analysis, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron features hundreds of AI-powered bots covering thousands of tickers, but only those demonstrating the strongest performance under current market conditions are highlighted in this dynamic, regularly updated section. Each bot employs distinct strategies, timeframes, and performance metrics across a diverse range of traded symbols. Explore the Trending AI Robots page to discover which automated strategies are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TGTX turns negative, indicating new downward trend
TGTX saw its Momentum Indicator move below the 0 level on July 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In of the 79 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 51 similar instances where the indicator moved out of overbought territory. In of the 51 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
TGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 214 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.661) is normal, around the industry mean (19.620). P/E Ratio (18.192) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (11.947) is also within normal values, averaging (420.906).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement